Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease - a [ 123I]-ADAM SPECT study

European Journal of Neurology

Volumn 18, Issue 5, 2011, Pages 750-755

  Beucke, J C ^a   Plotkin, M ^b   Winter, C ^b,e   Endrass, T ^a   Amthauer, H ^c   Juckel, G ^d   Kupsch, A ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University Clinic Magdeburg   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

123I ADAM; Depression in Parkinson's disease; Dopamine transporter; Levodopa; Parkinson's disease; Serotonin transporter; Single photon emission tomography

Indexed keywords

IODINE 123; LEVODOPA; SEROTONIN TRANSPORTER; SODIUM PERCHLORATE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG BINDING; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; EARLY DIAGNOSIS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79954590133     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03274.x     Document Type: Article

References (38)

1. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009; 72: S21-S26.
2. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007; 14: 523-528.
3. Bernheimer H, Birkmayer W, Hornykiewicz O. Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patientin mit Parkinson-Syndrom. Klinische Wochenschrift 1961; 39: 1056-1059.
4. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brain-stem serotonin-containing and substance-P-containing neurons in Parkinsons-disease. Brain Res 1990; 510: 104-107.
5. Jellinger K. Neuropathological substrate of dementia in Parkinsons-disease. Ann Neurol 1990; 28: 723-724.
6. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction - An C-11-WAY 100635 PET study. Neurology 2003; 60: 601-605.
7. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with I-123-beta-CIT SPECT. J Nucl Med 2003; 44: 870-876.
8. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008; 28: 441-444.
9. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008; 23: 1776-1780.
10. Kvernmo T, Harrter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-1078.
11. Carta N, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007; 27: 8011-8022.
12. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease - a community-based study. Arch Neurol 1996; 53: 175-179.
13. Leentjens AFG. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17: 120-126.
14. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104: 380-386.
15. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18: 414-418.
16. Schuurman AG, van den Akker M, Ensinck K, et al. Increased risk of Parkinson's disease after depression - A retrospective cohort study. Neurology 2002; 58: 1501-1504.
17. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population Mov Disord 2000; 15: 1112-1118.
18. Winter C, von Rumohr A, Mundt A, et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007; 184: 133-141.
19. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007; 130: 1799-1807.
20. Acton PD, Choi SR, Hou C, Plossl K, Kung HF. Quantification of serotonin transporters in nonhuman primates using [I-123]ADAM and SPECT. J Nucl Med 2001; 42: 1556-1562.
21. Huang WS, Ma KH, Cheng CY, et al. Imaging serotonin transporters with I-123-ADAM brain SPECT in healthy non-human primates. Nucl Med Commun 2004; 25: 515-519.
22. Ma KH, Huang WS, Huang SY, et al. Imaging serotonin transporters using [123I]ADAM SPECT in a parkinsonian primate model. Appl Radiat Isot 2008; 66: 1799-1803.
23. Newberg AB, Plossl K, Mozley PD, et al. Biodistribution and imaging with I-123-ADAM: a serotonin transporter imaging agent. J Nucl Med 2004; 45: 834-841.
24. Meltzer CC, Smith G, Price JC, et al. Reduced binding of [F-18]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998; 813: 167-171.
25. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
26. Herold N, Uebelhack K, Franke L, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [I-123]-ADAM. J Neural Transm 2006; 113: 659-670.
27. Plotkin M, Amthauer H, Klaffke S, et al. Combined I-123-FP-CIT and I-123-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112: 677-692.
28. Backstrom I, Bergstrom M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 1989; 486: 261-268.
29. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
30. Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000; 41: 36-44.
31. Huang Y, Hwang DR, Narendran R, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 2002; 22: 1377-1398.
32. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden SD, Goldstein M, et al. eds. Recent Developments in Parkinson's Disease II. New York: Macmillan, 1987.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
34. Beck AT, Steer RA. Beck Depression Inventory Manual. San Antonio, TX: The Psychological Corporation, 1987.
35. Wittchen HU, Zaudig M, Fydrich T. SKID: Strukturiertes Klinisches Interview für DSM-IV, Achse I. Göttingen: Hogrefe, 1997.
36. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008; 131: 120-131.
37. Heinz A, Ragan P, Jones DW, et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 1998; 155: 1544-1549.
38. Oya S, Choi SR, Hou C, et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 2000; 27: 249.